Investigational drug · Phase 2
IDE849
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "IDE849"
First trial start
2025
Oct 14, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IDE849", any sponsor or status.
Conditions studied
As listed on its trial records.
- Small-cell Lung Cancer
- Neuroendocrine Carcinomas
- Solid Tumor Show to Express DLL3
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "IDE849" as an intervention, largest first.
- A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung CancerRecruiting
IDEAYA BiosciencesIndustry
NCT07174583 · 262 participants (planned) · Start Oct 14, 2025 · Primary completion Jul 2029
Drug: IDE849; durvalumab and 2 more · For: Small-cell Lung Cancer; Neuroendocrine Carcinomas; Solid Tumor Show to Express DLL3
Sites: Denver, Colorado; Orlando, Florida; Fort Wayne, Indiana · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Small-cell Lung Cancer
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- ZG006Phase 38 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Neuroendocrine Carcinoma, Small Cell Lung Cancer, Solid Tumor
- GocatamigHPN328, MK-6070Phase 34 trials
Merck & Co. · Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage, Small-Cell Lung Cancer
- ZL-1310Phase 33 trials
Zai Lab (Shanghai) Co., Ltd. · Solid Tumors, Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma
- BL-M14D1Phase 32 trials
SystImmune Inc. · Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma
- IparomlimabPhase 32 trials
Qilu Pharmaceutical Co., Ltd. · Small-cell Lung Cancer, Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
- TuvonralimabPhase 32 trials
Qilu Pharmaceutical Co., Ltd. · Small-cell Lung Cancer, Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
- Atezolizumab followed by AtezolizumabPhase 31 trial
SystImmune Inc. · Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.